Related Experiment Video

Updated: Apr 29, 2026

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

10.1K

Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis

Xiaokai Wang1, Pinglin Lai2, Zhongmin Zhang1

  • 1Academy of Orthopedics of Guangdong Province, The Third Affiliated Hospital, Southern Medical University, Guangzhou, Guangdong 510630, P.R. China.

Oncology Reports
|May 21, 2014
PubMed

Insights

Targeting the mammalian target of rapamycin complex 2 (mTORC2) pathway enhances chemotherapy efficacy and reduces migration in osteosarcoma. Inhibition of mTORC2, not mTORC1, shows promise for osteosarcoma treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Dysregulation of the mammalian target of rapamycin (mTOR) signaling pathway is implicated in various human cancers.
  • The role of specifically inhibiting mammalian target of rapamycin complex 2 (mTORC2) in osteosarcoma remains largely unexplored.
  • mTORC2 presents a potential therapeutic target for osteosarcoma treatment.

Purpose of the Study:

  • To investigate the effects of mTORC2 inhibition on osteosarcoma cell migration and apoptosis.
  • To compare the efficacy of mTORC2 inhibition versus mTORC1 inhibition in combination with cisplatin for osteosarcoma treatment.
  • To provide a rationale for clinical trials involving mTORC1/2 inhibitors in osteosarcoma therapy.

Main Methods:

  • Utilized three human osteosarcoma cell lines (MG63, U2OS, Saos-2).
  • Inhibited mTORC2 using the specific inhibitor PP242 and siRNA targeting rictor.
  • Assessed cell migration via wound healing and Transwell assays; evaluated apoptosis using propidium iodide staining and Western blotting for PARP and caspase 7.

Main Results:

  • Inhibition of mTORC2, but not mTORC1, significantly reduced osteosarcoma cell migration.
  • Targeting mTORC2 enhanced cisplatin-induced apoptosis, evidenced by increased PARP cleavage and caspase 7 activation.
  • Inhibition of mTORC1 did not augment cisplatin's effect on apoptosis.

Conclusions:

  • mTORC2 is a critical regulator of osteosarcoma cell migration and apoptosis.
  • Targeting mTORC2 demonstrates superior therapeutic potential compared to mTORC1 inhibition in osteosarcoma.
  • Combination therapy with mTORC2 inhibitors and cisplatin warrants further investigation for osteosarcoma treatment.

More Related Videos

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

6.6K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K